Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologySierra Health and Life Gazyva Prior Auth Coverage …
    Ask Trek AI about this page
    Currentsierra health and lifePolicy 2026D0140A

    Gazyva (obinutuzumab) — Medical Benefit Drug Policy for Active Lupus Nephritis

    Customize your policy alerts

    Sign up for sierra health and life Policy 2026D0140A alerts

    Get alerted when Policy 2026D0140A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical benefit drug policy that governs coverage criteria for Gazyva (obinutuzumab) intravenous infusion for treatment of active lupus nephritis under Sierra Health and Life. Affects prescribers, infusion providers, and payers assessing prior authorization for this indication.

    Policy Summary
    Payersierra health and life
    PolicyGazyva (obinutuzumab) — Medical Benefit Drug Policy for Active Lupus Nephritis
    Policy CodePolicy 2026D0140A
    Change TypeNew policy
    Effective DateJan 1, 2026
    Next Review Date
    Key ActionObtain prior authorization documenting biopsy‑proven active lupus nephritis (or contraindication) and current use of at least one standard non‑biologic SLE therapy.
    SourceLink
    POLICY UPDATE CHANGES

    New Medical Benefit Drug Policy

    12 monthsauthorization period
    J9301HCPCS

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    M32.14Diagnosis code
    REGENCYPivotal trial

    Coverage Criteria for Gazyva (obinutuzumab)

    Initial Therapy — Covered when ALL of the following are met for initial therapy

    Covered when ALL of the following are met for initial therapy

    Initial therapy for active lupus nephritis: Diagnosis of active lupus nephritis; provider attestation that diagnosis is biopsy proven or biopsy is contraindicated; patient is currently receiving at least one standard of care treatment for active systemic lupus erythematosus (e.g., antimalarials, corticosteroids, or immunosuppressants) that is not a biologic; patient is not receiving Gazyva in combination with Benlysta (belimumab) or Lupkynis (voclosporin); Gazyva is dosed according to US Food and Drug Administration labeled dosing; prescribed by or in consultation with a rheumatologist or nephrologist; initial authorization is for no more than 12 monthsnone

    All conditions required

    Continuation Therapy — Covered when ALL of the following are met for continuation of therapy

    Covered when ALL of the following are met for continuation of therapy

    Continuation therapy for active lupus nephritis: Patient has previously received Gazyva injection for intravenous infusion; documentation of positive clinical response; patient is currently receiving at least one standard of care treatment for active systemic lupus erythematosus (e.g., antimalarials, corticosteroids, or immunosuppressants) that is not a biologic; patient is not receiving Gazyva in combination with belimumab or voclosporin; Gazyva is dosed according to US Food and Drug Administration labeled dosing; prescribed by or in consultation with a rheumatologist or nephrologist; authorization is for no more than 12 monthsnone

    All conditions required

    Use of Gazyva (obinutuzumab) in combination with Benlysta (belimumab) or Lupkynis (voclosporin) is explicitly excluded from covered indications under this policy. The coverage criteria for both initial and continuation therapy require that the patient is not receiving Gazyva in combination with belimumab or voclosporin as a condition of medical necessity and prior authorization.

    Therapy will be considered not medically necessary if it does not meet all of the specified initial or continuation criteria. Examples that would lead to non‑coverage include failure to document a diagnosis of active lupus nephritis (or provider attestation that biopsy is contraindicated when required), lack of concurrent use of at least one standard non‑biologic SLE therapy (e.g., antimalarials, corticosteroids, or immunosuppressants), absence of required documentation of prior benefit for continuation, dosing not consistent with the US FDA label, or use of Gazyva in combination with excluded agents such as belimumab or voclosporin. Meeting all listed conditions is required for authorization.

    Coding — HCPCS and Diagnosis Codes

    Applicable HCPCS CodesHCPCSCovered
    J9301Injection, obinutuzumab, 10 mg
    Referenced Diagnosis CodesICD-10
    M32.14Glomerular disease in systemic lupus erythematosus
    UPCR thresholds used in REGENCY
    Inclusion criterion (trial screening)Urine protein-to-creatinine ratio (UPCR) ≥ 1 g/g required for enrollment in REGENCY.
    Complete Renal Response (CRR) — core definitionUPCR < 0.5 g/g at Week 76.
    CRR additional requirementseGFR ≥ 85% of baseline and no rescue therapy, treatment failure, death, or early study withdrawal at Week 76.
    Proteinuric response (key secondary endpoint)UPCR < 0.8 g/g at Week 76 (with no rescue therapy, treatment failure, death, or early withdrawal).

    Provider Actions and Documentation Requirements

    Prior Authorization

    Prior authorization required for Gazyva for active lupus nephritis

    Prior authorization is required for Gazyva (obinutuzumab) when used to treat active lupus nephritis. The request must document diagnosis of active lupus nephritis and either biopsy-proven disease or an attestation that biopsy is contraindicated; dosing must follow the US FDA label; and initial and continuation authorizations are limited to no more than 12 months. Prescriptions must be by or in consultation with a rheumatologist or nephrologist, and the patient must not be receiving Gazyva in combination with belimumab (Benlysta) or voclosporin (Lupkynis).

    • Diagnosis of active lupus nephritis required
    • Provider attestation that diagnosis is biopsy proven or biopsy is contraindicated
    • Dosing per US FDA labeled dosing
    • Initial/continuation authorization limited to ≤ 12 months
    • Prescribed by or in consultation with a rheumatologist or nephrologist
    • Not used in combination with Benlysta (belimumab) or Lupkynis (voclosporin)

    Background

    Obinutuzumab (Gazyva) is a CD20‑directed monoclonal antibody that targets CD20 expressed on pre‑B and mature B lymphocytes and mediates B‑cell depletion through immune effector mechanisms, direct cell death, and complement activation.

    Definitions and Trial Endpoints

    Obinutuzumab (Gazyva) — mechanism of action
    Drug class and targetObinutuzumab (Gazyva) is a monoclonal antibody targeting the CD20 antigen on B lymphocytes.
    Mechanisms of B-cell depletionMediates B-cell lysis via engagement of immune effector cells including antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis.
    Direct and complement-mediated effectsAlso induces direct cell death by activating intracellular death signaling pathways and activates the complement cascade.
    Complete renal response (CRR) as defined in REGENCY
    CRR numeric UPCR thresholdUPCR < 0.5 g/g.
    CRR renal function requirementeGFR ≥ 85% of baseline (calculated by CKD-EPI 2009).
    Policy Summary
    Payersierra health and life
    PolicyGazyva (obinutuzumab) — Medical Benefit Drug Policy for Active Lupus Nephritis
    Policy CodePolicy 2026D0140A
    Change TypeNew policy
    Effective DateJan 1, 2026
    Next Review Date
    Key ActionObtain prior authorization documenting biopsy‑proven active lupus nephritis (or contraindication) and current use of at least one standard non‑biologic SLE therapy.
    SourceLink
    On This Page
    Coverage Criteria for Gazyva (obinutuzumab)Coding — HCPCS and Diagnosis CodesProvider Actions and Documentation RequirementsBackgroundDefinitions and Trial Endpoints
    Step Therapy

    Concurrent standard non-biologic therapy required

    Coverage requires the patient to be currently receiving at least one standard-of-care, non-biologic treatment for active systemic lupus erythematosus (examples listed in the policy include antimalarials, corticosteroids, or immunosuppressants). This concurrent therapy requirement applies to both initial and continuation authorizations.

    • Examples of acceptable concurrent therapies: antimalarials, corticosteroids, or immunosuppressants
    • Concurrent therapy must be a non-biologic agent
    Documentation Required

    Required clinical documentation

    Providers must attest that the diagnosis is biopsy proven or document why biopsy is contraindicated, and must supply documentation of prior Gazyva use and positive clinical response when requesting continuation. Documentation must also confirm concurrent non-biologic SLE therapy and that Gazyva is not being combined with belimumab or voclosporin.

    • Attestation that diagnosis is biopsy proven or biopsy is contraindicated
    • For continuation: documentation of prior Gazyva administration and positive clinical response
    • Evidence of concurrent standard non-biologic SLE therapy
    • Confirmation Gazyva is not used with Benlysta or Lupkynis
    Denial Risk

    Coverage contingent on meeting all listed criteria

    Coverage will be denied if the patient does not meet all required criteria for initial or continuation therapy, including diagnosis requirements, concurrent non-biologic therapy, absence of excluded combinations, dosing per FDA label, and required prescriber specialty/consultation.

    • Denial risk if biopsy-proven diagnosis or contraindication attestation is missing
    • Denial risk if concurrent non-biologic SLE therapy is not documented
    • Denial risk if Gazyva is prescribed in combination with belimumab or voclosporin
    • Denial risk if dosing does not follow the FDA label or prescriber specialty requirement is not met
    CRR event-free conditionNo rescue therapy, treatment failure, death, or early study withdrawal at Week 76.
    Context — primary endpoint timingCRR evaluated at Week 76 in the REGENCY trial.